181 related articles for article (PubMed ID: 37366281)
1. A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations.
Liu C; Shi P; Li Z; Li B; Li Z
Cancer Med; 2023 Aug; 12(16):16734-16743. PubMed ID: 37366281
[TBL] [Abstract][Full Text] [Related]
2. [
Xu HQ; Song LJ; Ding CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a [
Li M; Yao H; Zhang P; Zhang L; Liu W; Jiang Z; Li W; Zhao S; Wang K
Eur Radiol; 2023 May; 33(5):3354-3365. PubMed ID: 36547676
[TBL] [Abstract][Full Text] [Related]
6.
Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET/CT in patients with diffuse large B-cell lymphoma: Further risk stratification of the group with low-risk and high-risk NCCN-IPI.
Xu H; Ma J; Yang G; Xiao S; Li W; Sun Y; Sun Y; Wang Z; Zhao H
Eur J Radiol; 2023 Jun; 163():110798. PubMed ID: 37030099
[TBL] [Abstract][Full Text] [Related]
8. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [
Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227
[TBL] [Abstract][Full Text] [Related]
9. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718
[TBL] [Abstract][Full Text] [Related]
10. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
[TBL] [Abstract][Full Text] [Related]
11. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on
Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T;
Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452
[TBL] [Abstract][Full Text] [Related]
12. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
[TBL] [Abstract][Full Text] [Related]
13. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
[TBL] [Abstract][Full Text] [Related]
14. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline
Delaby G; Hubaut MA; Morschhauser F; Besson A; Huglo D; Herbaux C; Baillet C
Leuk Lymphoma; 2020 Jul; 61(7):1584-1591. PubMed ID: 32100597
[TBL] [Abstract][Full Text] [Related]
16. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
[TBL] [Abstract][Full Text] [Related]
17. Baseline [
Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
19. Influence of the methodological aspects of the dichotomization of total metabolic tumor volume measured through baseline fluorine-18 fluorodeoxyglucose PET on survival prediction in lymphoma.
Lue KH; Chen YH; Wu YF; Liu SH
Nucl Med Commun; 2023 Jan; 44(1):74-80. PubMed ID: 36514929
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
